Research graph
References from Waning effectiveness of mRNA COVID-19 vaccines against inpatient and emergency department encounters. Local targets link to admitted publications; unresolved targets remain external evidence.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
10.1056/nejmoa2034577 · 2020 · External reference
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
10.1056/nejmoa2035389 · 2021 · External reference
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
10.1056/nejmoa2110345 · 2021 · External reference
Waning Immunity after the BNT162b2 Vaccine in Israel
10.1056/nejmoa2114228 · 2021 · External reference
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
10.1056/nejmoa2114114 · 2021 · External reference
Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden
10.1016/s0140-6736(22)00089-7 · 2022 · External reference
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
10.1016/s0140-6736(22)00152-0 · 2022 · External reference
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study
2022 · External reference
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
10.1136/bmj-2022-072141 · 2022 · External reference
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
10.1038/s41591-022-01699-1 · 2022 · External reference
Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review.
10.1080/21645515.2023.2167410 · 2023 · External reference
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
10.1371/journal.pmed.1003992 · 2022 · External reference
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study
10.1016/s2213-2600(22)00101-1 · 2022 · External reference
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
10.1136/bmj-2021-068848 · 2021 · External reference
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
2022 · External reference
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
10.1016/s0140-6736(21)00947-8 · 2021 · External reference
Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans
10.1136/bmjopen-2022-063935 · 2022 · External reference
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
10.1001/jama.2021.19499 · 2021 · External reference
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States
10.1093/cid/ciab687 · 2022 · External reference
Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
10.1001/jamanetworkopen.2023.2598 · 2023 · External reference
SARS-CoV-2 Infection, Hospitalization, and Death in Vaccinated and Infected Individuals by Age Groups in Indiana, 2021‒2022.
10.2105/ajph.2022.307112 · 2023 · External reference
Covid-19 Vaccine Effectiveness in New York State
10.1056/nejmoa2116063 · 2022 · External reference
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina
10.1056/nejmoa2117128 · 2022 · External reference
The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.
10.1097/ede.0000000000001116 · 2020 · External reference
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
10.1001/jama.2022.0470 · 2022 · External reference
Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes
10.1001/jamanetworkopen.2022.32760 · 2022 · External reference
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
10.1056/nejmoa2110362 · 2021 · External reference
Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System.
10.1093/cid/ciaa1419 · 2021 · External reference
Demographic Disparities in Clinical Outcomes of COVID-19: Data From a Statewide Cohort in South Carolina.
10.1093/ofid/ofab428 · 2021 · External reference
Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis
10.1016/j.ijid.2020.07.029 · 2020 · External reference
Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.
2023 · External reference
